Valeant Pharmaceuticals (VRX) PT Raised to $209 at Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with a price target of $209.00 (from $192.00). Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
